2011; Pérez-Belmonte et al. 2017), and inhibiting SREBP-1 led to lower serum cholesterol levels, further alleviating AS (Karasawa et al. 2011). PI3K/AKT is the upstream signaling pathway of SREBP-1, whose activation increased the expression of SREBP-1 (Jeon and Osborne 2012). Recent studies showed that PI3K/AKT signaling is significantly upregulated in patients with nonalcoholic fatty liver disease, one of the risk factors for AS, and inhibitors against PI3K and AKT have potential regulatory effects on lipid metabolism (Aljabban et al. 2022). Here, SREBF1 is linked to metabolic dysfunction-associated steatotic liver disease.